Delivery Order SPE2DB22D3004-SPE2DB25FRM02
Award Date
7/16/25
Potential Completion Date
7/17/25
Potential Value
$1.7K
Federal Agency
Defense Logistics Agency
Awardee
Amerisourcebergen Drug Corp
Ultimate Awardee
Not listed
NAICS Category
424210 - Drugs and Druggists' Sundries Merchant Wholesalers
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award is for the delivery of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML pharmaceutical products to the Defense Logistics Agency (DLA), a defense agency. The $1,684.96 firm fixed-price delivery order was awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, on June 17, 2025, with a completion date of June 18, 2025. The contract is not set aside and does not mention any subcontractors. AmerisourceBergen Drug Corp holds a substantial $999,999,999.00...
This federal contract award is for the delivery of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a pharmaceutical product, to the U.S. government. The contract, valued at $1,684.96, was awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, by the Defense Logistics Agency (DLA), a defense agency. The contract is a Firm Fixed Price Delivery Order with an ultimate completion date of July 10, 2025. It is not designated as a set-aside contract, indicating open competition....
This federal contract award is for the delivery of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a vaccine, to the Defense Logistics Agency (DLA). The $1,850.36 firm-fixed price delivery order was awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, on July 17, 2025 with an ultimate completion date of July 18, 2025. The contract was not set aside and was competitively awarded. Amerisourcebergen Drug Corp holds a significant $999,999,999.00 Indefinite Delivery Contract (IDC) with...
This federal contract award is for the delivery of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a pharmaceutical product, to the Defense Logistics Agency (DLA), a defense agency. The contract, valued at $1,577.28, was awarded to AmerisourceBergen Drug Corp, a major supplier of pharmaceutical products and medical supplies to the U.S. federal government. The contract is a Delivery Order with a Firm Fixed Price pricing type and an ultimate completion date of April 17, 2024. AmerisourceBergen Drug Corp...
This federal contract award is for the delivery of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a pharmaceutical product, to the Defense Logistics Agency (DLA). The contract has a ceiling value of $16,849.60 and is a Firm Fixed Price Delivery Order, awarded to the prime contractor Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract has an ultimate completion date of May 14, 2025 and is not designated as a set-aside. Amerisourcebergen Drug Corp...
This federal contract award is for the delivery of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML vaccines to the Defense Logistics Agency (DLA). The contract, valued at $69,524.40, was awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a Delivery Order with a Firm Fixed Price pricing type and an ultimate completion date of September 11, 2024. The contract is not designated with a set-aside requirement, indicating open competition....
This federal contract award is for the delivery of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a pharmaceutical product, to the Defense Logistics Agency (DLA). The contract, valued at $1,182.96, was awarded to Amerisourcebergen Drug Corp's Corporate Office Division, a major supplier of pharmaceutical products and medical supplies to the U.S. federal government, particularly the Department of Defense (DoD) and Veterans Affairs (VA) healthcare systems. The contract is a Delivery Order under a larger...
This federal contract award is for the delivery of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a pharmaceutical product, to the Defense Logistics Agency (DLA), a defense agency. The contract has a ceiling value of $2,527.44 and is a firm fixed price delivery order. The prime contractor is Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider based in Conshohocken, Pennsylvania. The contract is not set aside and is open to full and open competition. The...
This federal contract award is for the delivery of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a pharmaceutical product, to the Defense Logistics Agency (DLA). The prime contractor is Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc. The contract has a ceiling value of $7,664.20 and an ultimate completion date of November 15, 2023. This is a firm fixed-price delivery order contract, and there is no set-aside designation. Amerisourcebergen Drug Corp holds a significant...
This federal contract award is for the delivery of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a pharmaceutical product, to the Defense Logistics Agency (DLA). The contract has a ceiling value of $2,655.80 and is a firm fixed-price delivery order. The prime contractor is Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is not set-aside and is open to full and open competition. Amerisourcebergen Drug Corp holds a significant Indefinite...